Beneficial Effects of Montelukast against Cisplatin-Induced Acute Renal Damage in Rats

Basit Öğe Kaydı
dc.authoridTürköz, Yusuf/0000-0001-5401-0720
dc.authoridVardı, Nigar/0000-0003-0576-1696
dc.authoridTaşlidere, Aslı Cetin/0000-0003-3902-3210
dc.authoridKose, Evren/0000-0002-0246-2589
dc.authoridBeytur, Ali/0000-0002-7870-3318
dc.authoridSarihan, Mehmet Ediz/0000-0002-1266-4213
dc.authorwosidTürköz, Yusuf/ABG-7931-2020
dc.authorwosidDogan, Zumrut yılmaz/V-5131-2018
dc.authorwosidDoğan, Zümrüt/GQP-2535-2022
dc.authorwosidVardı, Nigar/C-9549-2018
dc.authorwosidTaşlidere, Aslı Cetin/AAB-3979-2021
dc.authorwosidKose, Evren/ABG-9908-2020
dc.authorwosidBeytur, Ali/AAA-2823-2021
dc.contributor.authorBeytur, Ali
dc.contributor.authorKose, Evren
dc.contributor.authorSarihan, Mehmet Ediz
dc.contributor.authorSapmaz, Hilal Irmak
dc.contributor.authorDogan, Zumrut
dc.contributor.authorCetin, Asli
dc.contributor.authorVardi, Nigar
dc.date.accessioned2024-08-04T20:35:46Z
dc.date.available2024-08-04T20:35:46Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: In this study, the therapeutic and protective effects of montelukast against cisplatin (CP)-induced acute renal damage were investigated. Materials and Methods: Thirty-five female rats were divided into five groups as follows: (1) control, (2) montelukast (10 mg/kg daily for 10 days per-oral (p.o.), (3) CP (single dose 7 mg/kg intraperitoneally (i.p.)), (4) CP + montelukast (10 mg/kg daily for 10 days p.o., after 3 days of the injection of CP), (5) montelukast (10 mg/kg daily for 10 days p.o.) + CP (single dose 7 mg/kg i.p., after the last dose of montelukast). At the end of the experiment, malondialdehyde (MDA), a lipid peroxidation product, myeloperoxidase (MPO), and reduced glutathione (GSH) levels were determined in the renal tissue. Also, blood urea nitrogen (BUN) and creatinine (Cr) levels were assayed from the trunk blood samples. Results: CP treatment caused a significant elevation of MDA, MPO, BUN, and Cr levels when compared with the control group. Also, GSH levels were found to be reduced due to the CP treatment. Montelukast administration after CP injection ameliorated all of these parameters. Our histopathological findings (marked swelling of epithelial cells, tubular dilatation, tubular desquamation, and loss of brush border in the kidney) were consistent with the biochemical results. Conclusion: Montelukast treatment after CP injection exerted therapeutic effects against CP-induced acute kidney damage.en_US
dc.description.sponsorshipInonu University [2010/59]en_US
dc.description.sponsorshipThis study was supported by a grant from The Scientific Research Fund of Inonu University (2010/59).en_US
dc.identifier.doi10.3109/0886022X.2011.647305
dc.identifier.endpage349en_US
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue3en_US
dc.identifier.pmid22260262en_US
dc.identifier.scopus2-s2.0-84857577387en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage343en_US
dc.identifier.urihttps://doi.org/10.3109/0886022X.2011.647305
dc.identifier.urihttps://hdl.handle.net/11616/95582
dc.identifier.volume34en_US
dc.identifier.wosWOS:000300558700015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcisplatinen_US
dc.subjectmontelukasten_US
dc.subjectrenal injuryen_US
dc.subjectmalondialdehydeen_US
dc.subjectraten_US
dc.titleBeneficial Effects of Montelukast against Cisplatin-Induced Acute Renal Damage in Ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu